Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Acceleron Pharma Inc.    XLRN

ACCELERON PHARMA INC.

(XLRN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/21/2021 01/22/2021 01/25/2021 01/26/2021 01/27/2021 Date
124.64(c) 124.61(c) 125.88(c) 120.95(c) 114.5(c) Last
284 890 261 663 228 134 228 672 342 096 Volume
-1.46% -0.02% +1.02% -3.92% -5.33% Change
More quotes
Financials (USD)
Sales 2020 99,4 M - -
Net income 2020 -142 M - -
Net cash position 2020 759 M - -
P/E ratio 2020 -45,7x
Yield 2020 -
Sales 2021 164 M - -
Net income 2021 -125 M - -
Net cash position 2021 704 M - -
P/E ratio 2021 -55,0x
Yield 2021 -
Capitalization 6 899 M 6 899 M -
EV / Sales 2020 61,8x
EV / Sales 2021 37,9x
Nbr of Employees 237
Free-Float 87,6%
More Financials
Company
Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that... 
More about the company
Notations Surperformance© of Acceleron Pharma Inc.
Trading Rating : Investor Rating :
More Ratings
All news about ACCELERON PHARMA INC.
01/21IMARA : Announces the Appointment of Kenneth Attie M.D. as Chief Medical Officer
AQ
01/11ACCELERON PHARMA INC : Regulation FD Disclosure, Financial Statements and Exhibi..
AQ
01/07ACCELERON PHARMA : Insiders at Acceleron Pharma (XLRN) Make Significant Stock Sa..
MT
01/06INSIDER TRENDS : Acceleron Pharma Insider Sale for Taxes Adds to 90-Day Selling ..
MT
01/04ACCELERON PHARMA : to Participate in the 39th Annual J.P. Morgan Healthcare Conf..
BU
2020ACCELERON PHARMA : Barclays Adjusts Acceleron Pharma PT to $150 From $133, Maint..
MT
2020ACCELERON PHARMA : Morgan Stanley Adjusts Acceleron Pharma PT to $135 From $130,..
MT
2020ACCELERON PHARMA : Receives European Commission Orphan Designation for Sotaterce..
MT
2020ACCELERON PHARMA : Receives Orphan Designation from the European Commission (EC)..
BU
2020Acceleron Wins US FDA Orphan Drug Designation for ACE-1334 for Systemic Scler..
MT
2020ACCELERON PHARMA : Receives FDA Orphan Drug Designation for ACE-1334 for the Tre..
BU
2020Oppenheimer Adjusts Acceleron Pharma's Price Target to $131 from $120 on Sota..
MT
2020ACCELERON PHARMA : Presents New Data from the PULSAR Phase 2 Trial, Preclinical ..
AQ
2020ACCELERON PHARMA : Presents Preliminary Interim Data from the SPECTRA Phase 2 Tr..
AQ
2020Acceleron Pharma Reports Positive Preliminary Outcomes From Sotatercept Trial..
MT
More news
News in other languages on ACCELERON PHARMA INC.
2020WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
2019ACCELERON PHARMA INC : Veröffentlichung des Quartalsergebnisses
2019ACCELERON PHARMA INC : publication des résultats trimestriels
2018ACCELERON PHARMA : Die Celgene Corporation und Acceleron Pharma geben bei der AS..
2018ASH 2018 : Celgene Corporation e Acceleron Pharma annunciano i risultati dello s..
More news
Analyst Recommendations on ACCELERON PHARMA INC.
More recommendations
Chart ACCELERON PHARMA INC.
Duration : Period :
Acceleron Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACCELERON PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 135,38 $
Last Close Price 114,50 $
Spread / Highest target 46,7%
Spread / Average Target 18,2%
Spread / Lowest Target -12,7%
EPS Revisions
Managers and Directors
NameTitle
Habib J. Dable President, Chief Executive Officer & Director
Francois Nader Non-Executive Chairman
Christopher Rovaldi SVP-Program Management & Operations
Lisa Wyman Vice President-Operations
Kevin F. McLaughlin Chief Financial Officer, Treasurer & Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
ACCELERON PHARMA INC.-10.50%6 899
GILEAD SCIENCES, INC.12.39%83 610
WUXI APPTEC CO., LTD.36.65%64 891
VERTEX PHARMACEUTICALS-4.69%61 795
REGENERON PHARMACEUTICALS6.72%57 427
BEIGENE, LTD.24.12%32 675